Pre-made Albiglutide benchmark antibody (Peptide Protein fusion , anti-GLP1R therapeutic antibody, Anti-GLP-1-R/GLP-1R Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Albiglutide benchmark antibody (Peptide Protein fusion , anti-GLP1R therapeutic antibody, Anti-GLP-1-R/GLP-1R Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Albiglutide (trade names Eperzan in Europe and Tanzeum in the US) is a glucagon-like peptide-1 agonist (GLP-1 agonist) drug marketed by GlaxoSmithKline (GSK) for treatment of type 2 diabetes. As of 217 it is unclear if it affects a person's risk of death.[1] GSK has announced that it intends to withdraw the drug from the worldwide market by July 218 for economic reasons.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-724-1mg	1mg	3090
GMP-Bios-INN-724-10mg	10mg	Inquiry
GMP-Bios-INN-724-100mg	100mg	Inquiry
GMP-Bios-INN-724-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Albiglutide Biosimilar, Peptide Protein Fusion targeting GLP1R: (Glp-1)2 Peptide-Albumin(Alb) Fusion Protein targetingGLP-1-R/GLP-1R
INN Name	Albiglutide
Target	GLP1R
Format	Peptide Protein fusion
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - (GCG (glucagon) 98-127 (glucagon-like peptide 1, GLP1) 7- 36)2 - ALB (albumin, human serum albumin, HSA) 25-609
VD LC	Fusion - (GCG (glucagon) 98-127 (glucagon-like peptide 1, GLP1) 7- 36)2 - ALB (albumin, human serum albumin, HSA) 25-609
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	GlaxoSmithKline (Brentford UK)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0